auto-fix: strip 10 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

inbox/queue/2026-04-28-calibrate-clinical-quality-positioning-glp1-2025.md

@@ -56,8 +56,8 @@ The GLP-1 behavioral support market is stratifying:
 **What I expected but didn't find:** Calibrate's revenue or member numbers. The company is private and didn't disclose 2025 financials. The 2026 outcomes data release (promised in the source) would be a strong future archive — employer outcomes data is the commercial proof point for clinical quality claims.
 
 **KB connections:**
-- [[healthcares defensible layer is where atoms become bits]] — Calibrate represents a different atoms-to-bits model: the physical layer is prescribing + lab-based measurement (lipids, glycemic) rather than CGM
-- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent]] — Calibrate's multi-biomarker outcome tracking is the VBC equivalent for GLP-1
+- healthcares defensible layer is where atoms become bits — Calibrate represents a different atoms-to-bits model: the physical layer is prescribing + lab-based measurement (lipids, glycemic) rather than CGM
+- SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent — Calibrate's multi-biomarker outcome tracking is the VBC equivalent for GLP-1
 
 **Extraction hints:**
 - No standalone claim — Calibrate is supporting evidence for a broader "clinical quality stratification" pattern

inbox/queue/2026-04-28-glp1-market-stratification-access-first-vs-clinical-quality.md

@@ -68,9 +68,9 @@ Previous session (2026-04-27) had identified the atoms-to-bits signal in GLP-1 a
 **What I expected but didn't find:** A counterexample — a company without physical integration that is commercially thriving in GLP-1 behavioral support. Ro and Found (Tier 3) are alive but I found no evidence of strong growth or profitability. If a pure-software behavioral coaching company were thriving, that would challenge the stratification claim.
 
 **KB connections:**
-- [[healthcares defensible layer is where atoms become bits]] — STRONGEST CONFIRMATION in the KB
-- [[the healthcare attractor state is a prevention-first system]] — GLP-1 behavioral support is a microcosm of the prevention-first attractor, with the commercial outcomes now visible
-- [[proxy inertia is the most reliable predictor of incumbent failure]] — WeightWatchers is the proxy inertia case: behavioral community model profitable until GLP-1 disruption made the transition unavoidable
+- healthcares defensible layer is where atoms become bits — STRONGEST CONFIRMATION in the KB
+- the healthcare attractor state is a prevention-first system — GLP-1 behavioral support is a microcosm of the prevention-first attractor, with the commercial outcomes now visible
+- proxy inertia is the most reliable predictor of incumbent failure — WeightWatchers is the proxy inertia case: behavioral community model profitable until GLP-1 disruption made the transition unavoidable
 
 **Extraction hints:**
 - CLAIM: "The GLP-1 behavioral support market has stratified by physical integration level, with atoms-to-bits companies (Omada $260M profitable; Noom $100M run-rate) outperforming behavioral-only companies (WeightWatchers bankrupt) — validating the atoms-to-bits thesis with commercial outcomes rather than theoretical prediction" — confidence: likely

inbox/queue/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md

@@ -62,8 +62,8 @@ Key findings:
 
 **KB connections:**
 - [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] — LLM coaching faces the same human oversight degradation risk
-- [[prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost]] — LLM coaching companies face same tension: FDA oversight vs. scale economics
-- [[healthcares defensible layer is where atoms become bits]] — LLM coaching is pure bits → confirms it commoditizes; physical integration is the moat
+- prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost — LLM coaching companies face same tension: FDA oversight vs. scale economics
+- healthcares defensible layer is where atoms become bits — LLM coaching is pure bits → confirms it commoditizes; physical integration is the moat
 
 **Extraction hints:**
 - CLAIM: "LLM behavioral coaching matches human coach message quality after refinement but fails to achieve clinical equivalence due to privacy, bias, and safety concerns — limiting LLM commoditization to low-end GLP-1 prescribing markets, not clinical behavioral support" — confidence: experimental

inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md

@@ -66,7 +66,7 @@ Noom had struggled commercially before GLP-1 — it was a behavioral app facing
 3. Noom's D2C tech-forward brand was better positioned for clinical innovation than WW's community brand
 
 **KB connections:**
-- [[healthcares defensible layer is where atoms become bits]] — Noom is adding physical biomarker testing to remain defensible
+- healthcares defensible layer is where atoms become bits — Noom is adding physical biomarker testing to remain defensible
 - [[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]] — Noom's model suggests that PERIODIC biomarker testing (not continuous wearables) may be the more practical clinical integration layer
 
 **Extraction hints:**

inbox/queue/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation.md

@@ -61,7 +61,7 @@ Omada is not a pure software play — the CGM integration creates physical data
 - [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]] — DIRECT CONFIRMATION
 - [[the atoms-to-bits spectrum positions industries between defensible-but-linear and scalable-but-commoditizable with the sweet spot where physical data generation feeds software that scales independently]] — CONFIRMED
 - [[consumer CGMs are going mainstream as behavioral change tools not clinical diagnostics because real-time glucose visibility changes food choices even without randomized trial evidence]] — Omada's model is the institutional version of this consumer pattern
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history]] — Omada's growth is riding this wave
+- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history — Omada's growth is riding this wave
 
 **Extraction hints:**
 - CLAIM: "Omada Health's IPO profitability at $260M revenue validates the atoms-to-bits model in GLP-1 behavioral support: CGM-integrated behavioral coaching achieves 67% vs 47% adherence and 28% greater weight loss while scaling to 886K members" — confidence: likely (commercial outcome, not just adherence)

inbox/queue/2026-04-28-weightwatchers-bankruptcy-glp1-disruption-clinical-pivot.md

@@ -55,7 +55,7 @@ At the time of bankruptcy, WeightWatchers had ~$700M revenue; Omada had $260M re
 **What I expected but didn't find:** Evidence that WeightWatchers is now meaningfully integrating CGM or physical monitoring in its clinical pivot. The post-bankruptcy transformation appears to be adding telehealth prescribing (Sequence) but not physical device integration. If the "clinical-behavioral hybrid" is just prescribing + coaching without physical monitoring, it still won't have the atoms-to-bits moat.
 
 **KB connections:**
-- [[healthcares defensible layer is where atoms become bits]] — WeightWatchers is the counter-factual proof: no physical data integration → bankruptcy despite behavioral expertise
+- healthcares defensible layer is where atoms become bits — WeightWatchers is the counter-factual proof: no physical data integration → bankruptcy despite behavioral expertise
 - [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] — WW's profitable behavioral program made the Sequence pivot feel optional until it wasn't
 - [[prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near-zero marginal cost software]] — related failure mode: pure software healthcare businesses face structural unit economics problems